放化疗与度伐利尤单抗的给药时间与肺癌肿瘤控制的关联
回顾178例不可手术的局部晚期非小细胞肺癌患者,接受根治性放化疗后度伐利尤单抗治疗。中位随访48.0个月,中位无进展生存期26.2个月、总生存期50.0个月。多变量分析显示,超过50%的放疗在日落3小时内完成与进展风险降低独立相关(HR 0.39,p=0.017),而超过50%的度伐利尤单抗输注在日落3小时内完成与远处转移风险增加独立相关(HR 2.13,p=0.025)。
要点
- 超过50%放疗在日落3小时内完成与进展风险降低独立相关(HR 0.39,p=0.017)。
- 超过50%度伐利尤单抗输注在日落3小时内完成与远处转移风险增加独立相关(HR 2.13,p=0.025)。
- 化疗给药时间与疾病结局无关。
核心结论
- 放疗和度伐利尤单抗输注的时间点可能与局部晚期非小细胞肺癌的疾病控制相关,最佳治疗时间取决于治疗方式。
研究设计与样本
- 回顾性审查2017年5月至2022年8月期间接受根治性放化疗后度伐利尤单抗治疗的178例连续不可手术局部晚期非小细胞肺癌患者。
主要发现
- 从度伐利尤单抗开始中位随访48.0个月,中位无进展生存期26.2个月,中位总生存期50.0个月,中位局部区域控制未达到,中位无远处转移生存期41.0个月。
- 接受超过50%放疗在日落3小时内完成(N=23)与≤50%(N=155)相比与更年轻年龄相关,其余队列间无其他差异。
- 接受超过50%度伐利尤单抗输注在日落3小时内完成(N=23)与≤50%(N=155)相比患者特征无显著差异。
- 多变量分析中,超过50%放疗在日落3小时内完成与进展风险降低独立相关(HR 0.39,p=0.017)和远处转移风险降低独立相关(HR 0.27,p=0.007)。
- 超过50%度伐利尤单抗输注在日落3小时内完成与远处转移风险增加独立相关(HR 2.13,p=0.025)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/PURPOSE: The circadian clock governs the expression of genes related to immunity and DNA repair. We investigated whether the time of day of radiotherapy and/or systemic therapy infusions (chemotherapy or anti-PD-L1) are associated with disease control and survival in locally advanced non-small cell lung cancer (LA-NSCLC). MATERIALS/METHODS: 178 consecutive patients with inoperable LA-NSCLC who received definitive chemoradiotherapy followed by durvalumab between 5/2017-8/2022 were reviewed. Outcomes evaluated included progression-free survival (PFS), distant metastasis-free survival (DMFS), locoregional control (LRC), and overall survival (OS). RESULTS: At a median follow up of 48.0 mo from durvalumab initiation, median PFS and OS were 26.2 mo and 50.0 mo, respectively. Median LRC and DMFS were not reached and 41.0 mo, respectively. Receiving > 50 % (N = 23) versus ≤ 50 % (N = 155) of radiotherapy treatments within 3 h of sunset was associated with younger age; otherwise, there were no other differences between cohorts. There were no significant differences in characteristics between patients who received > 50 % (N = 23) versus ≤ 50 % (N = 155) of durvalumab infusions within 3 h of sunset. On multivariable analysis, receiving > 50 % of radiotherapy treatments within 3 h of sunset was independently associated with reduced risk for progression (HR 0.39, p = 0.017) and distant metastasis (HR 0.27, p = 0.007); conversely, receiving > 50 % of durvalumab infusions within 3 h of sunset was independently associated with increased risk for distant metastasis (HR 2.13, p = 0.025). The timing of chemotherapy was not associated with disease outcomes. CONCLUSION: The time of day of radiotherapy and durvalumab infusion may be associated with disease control in LA-NSCLC, and the optimal time of treatment depends on the treatment modality.
引用
- McMillan MT, Shepherd A, Cooper AJ, et al. Association of the time of day of chemoradiotherapy and durvalumab with tumor control in lung cancer. Radiother Oncol. 2024. PMID: 39626792. doi:10.1016/j.radonc.2024.110658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。